Return To The Previous Page

Buy a Package

Number Of Visible Items Remaining : -63 Item

Dose modification guidelines for cetuximab based upon cutaneous adverse reaction

Dose modification guidelines for cetuximab based upon cutaneous adverse reaction

Severe acneiform rash	Initial management	Outcome	Dose modification
First occurrence	Delay infusion 1 to 2 weeks	Improvement	Continue at 250 mg/m²
First occurrence	Delay infusion 1 to 2 weeks	No improvement	Discontinue cetuximab
Second occurrence	Delay infusion 1 to 2 weeks	Improvement	Reduce dose to 200 mg/m²
Second occurrence	Delay infusion 1 to 2 weeks	No improvement	Discontinue cetuximab
Third occurrence	Delay infusion 1 to 2 weeks	Improvement	Reduce dose to 150 mg/m²
Third occurrence	Delay infusion 1 to 2 weeks	No improvement	Discontinue cetuximab
Fourth occurrence	Discontinue cetuximab

Erbitux (cetuximab) package insert, ImClone LLC, August, 2013.

Graphic 58603 Version 7.0